Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Completed 2Unknown 1Terminated 1Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 5NET 4Gastrointestinal 3Sarcoma 2Tumor-Agnostic 1Thoracic 1Other solid neoplasm 1Lymphoid 1Head & Neck 1Gynecologic 1

Conditions

Sarcoma 2Sarcoma, Ewing 1Rhabdomyosarcoma 1Osteosarcoma 1Neuroectodermal Tumors, Primitive 1Neoplasms 1Lymphoma 1Carcinoid Tumor 1

Interventions

Radiotherapy 144Doxorubicin 112Temozolomide 110Cyclophosphamide 110Filgrastim 79Ifosfamide 70Imatinib Mesylate 69Etoposide 69Bevacizumab 55Vincristine 51Gemcitabine 50Peripheral Blood Stem Cell Transplantation 47Irinotecan 43Methotrexate 39Cisplatin 36Carboplatin 36Radiation 35fludarabine phosphate 34Busulfan 34pazopanib 32Sirolimus 30Melphalan 30Trabectedin 29Docetaxel 27Chemotherapy, Adjuvant 27Cyclosporine 25Carmustine 25sargramostim 24Surgical Procedures, Operative 23Sunitinib 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × surufatinib × Sarcoma × Clear all
NCT02549937 2024-07-10

A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors

Hutchmed

Phase 1/2 Completed
130 enrolled 30 charts
EndocrineSarcoma

Carcinoid Tumor, Neoplasms, Sarcoma, Neuroectodermal Tumors, Primitive

NCT05093322 2024-06-07

A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors

Hutchmed

Phase 1/2 Completed
13 enrolled 17 charts
LymphoidSarcoma

Lymphoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡